Deploying a Patient-First Framework to Accelerate Recruitment & Reduce Overall Trial Timelines

The accelerated growth of patient-centric trials is driven by innovations in remote patient monitoring (RPM) and precision medicine. Insider intelligence estimates that 70.6 million US patients, or 26.2% of the population, will use RPM tools by 2025.

With this growth comes new potential, as sponsors and CROs gain the ability to drive better patient outcomes, increase patient adherence, improve health metrics, and ensure seamless patient onboarding.

However, it takes more than simply adding tools to your trial to gain this insight: Join us on Thursday, November 10, 2022 as experts from Medable’s Digital Medicine and Partner Technologies area showcase:

• How digital data-flow designs, when mapped with clinical objectives, can support access to wider patient populations improving diversity & inclusion
• How to increase operational efficiencies & enhance end-to-end patient enrollment, engagement, and retention
• How first-hand experience in dermatology and oncology studies has identified robust patient populations which bring greater benefits to study outcomes
• How the financial value of implementing DCTs can be realized in your organization

Speakers

Gillian Livock, SVP & GM Digital Endpoints, Medable

Gill has over 20 years of experience in life sciences and clinical trials, most recently as Global VP of Corporate Business Development and Partnerships for Definiens AG, part of the AstraZeneca group. Gill is instrumental in supporting partnerships where digital trial strategies can deliver decentralized solutions and RWE can drive digital therapeutics.

Message Presenter

Michael Howell, Ph.D., Chief Scientific Officer, DermTech

Michael Howell, Ph.D., is an immunologist with more than 20 years of experience in the government, academia, and the biopharma/biotech sectors. Prior to joining DermTech, Dr. Howell was a faculty member at National Jewish Health and held increasing positions of responsibility at Boehringer Ingelheim, MedImmune/AstraZeneca, and Incyte Corporation. Dr. Howell has previously led research and development teams dedicated to the discovery of novel therapies for dermatology and the integration of novel biomarker approaches including adhesive tape strips into clinical development. His efforts have led to the approval of multiple therapies, novel diagnostic approaches to patient treatment, and have been highlighted in more than 50 publications and numerous patents. Dr. Howell received his Ph.D. in Immunology from West Virginia University and completed his post-doctoral training at National Jewish Health.

Message Presenter

Musaddiq (Muz) Khan, VP Therapeutic Area Solutions - Customer Value Team, Medable

Muz has been involved in clinical research for over 17 years, across all phases of clinical drug development. Following his academic research on improving early diagnosis in lung cancer, he moved into industry, working on clinical trials across a range of therapeutic areas. He has held various, operationally focused roles primarily on early phase clinical development programmes at Parexel, Roche and AstraZeneca. Following completion of his Executive MBA from the University of Cambridge in 2018 with a dissertation on “Developing a Digital Health Strategy for Early Clinical Development” he took on the role of Director, Clinical Program Operations in the Exploratory Medicine Pharmacology group at Eli Lilly where he was lucky enough to lead the operational delivery of the First in Human study on their Covid-19 Antibody programme. Muz is the VP Therapeutic Area Solutions – Customer Value Team at Medable, providing cross-functional support to help translate DCT capabilities into clinical operational delivery.

Message Presenter